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The baroreflex response is an essential component of the cardiovascular regulation that
buffers abrupt changes in blood pressure to maintain homeostasis. Urotensin II (UII)
and its receptor UT are present in the brain and in peripheral cardiovascular tissues
of fish and mammals. Intracerebroventricular (ICV) injection of UII in these vertebrates
provokes hypertension and tachycardia, suggesting that the cardio-inhibitory baroreflex
response is impaired. Since nothing is known about the effect of UII on the cardiac
baroreflex sensitivity (BRS), we decided to clarify the changes in spontaneous BRS using
a cross spectral analysis technique of systolic blood pressure (SBP) and R–R interval
variabilities after ICV and intra-arterial (IA) injections of trout UII in the unanesthetized
trout. We contrasted the effects of UII with those observed for the UII-related peptides
(URP), URP1 and URP2. Compared with vehicle-injected trout, ICV injection of UII
(5–500 pmol) produced a gradual increase in SBP, a decrease in the R–R interval
(reflecting a tachycardia) associated with a dose-dependent reduction of the BRS. The
threshold dose for a significant effect on these parameters was 50 pmol (BRS; −55%;
1450 ± 165 ms/kPa vs. 3240 ± 300 ms/kPa; P < 0.05). Only the 500-pmol dose of
URP2 caused a significant increase in SBP without changing significantly the R–R interval
but reduced the BRS. IA injection of UII (5–500 pmol) caused a dose-dependent elevation
of SBP. Contrasting with the ICV effects of UII, the R–R interval increased (reflecting a
bradycardia) up to the 50-pmol dose while the BRS remained unchanged (50 pmol;
2530 ± 270 ms/kPa vs. 2600 ± 180 ms/kPa; P < 0.05). Nonetheless, the highest dose
of UII reduced the BRS as did the highest dose of URP1. In conclusion, the contrasting
effect of low picomolar doses of UII after central and peripheral injection on the BRS
suggests that only the central urotensinergic system is involved in the attenuation of the
BRS. The limited and quite divergent effects of URP1 and URP2 on the BRS, indicate
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that the action of UII is specific for this peptide. Further studies are required to elucidate
the site(s) and mechanisms of action of UII on the baroreflex pathways. Whether such
effects of central UII on the BRS exist in mammals including humans warrants further
investigations.
Keywords: urotensin II, urotensin II-related peptide 1, urotensin II-related peptide 2, intracerebroventricular
injection, peripheral injection, baroreflex, autonomic nervous system, trout
INTRODUCTION
Urotensin II (UII) is a cyclic neuropeptide that was originally
isolated and purified from the caudal neurosecretory system
of the teleost fish Gillichthys mirabilis and later characterized
in mammals (Pearson et al., 1980; Vaudry et al., 2010, 2015).
UII belongs to a family of structurally related peptides that
includes UII and UII-related peptides (URPs) called URP, URP1,
and URP2. In the teleost lineage, the four peptides are present
but only two of them, UII and URP, are found in tetrapods
(Tostivint et al., 2013). UII and URP bind to an ancestral
(UII) receptor, termed UT, and the two peptides activate this
receptor with similar potency. In teleost fish, which possess
different UT subtypes (Tostivint et al., 2014), UII, URPs, and
UT are present in the central nervous system (CNS) i.e., in
the brainstem and spinal cord (Lu et al., 2006; Nobata et al.,
2011; Parmentier et al., 2011; Quan et al., 2015) and UT
has been identified in various peripheral organs including the
cardiovascular system (Lu et al., 2006). In mammals, UII and
URP genes are mostly and differentially expressed in cholinergic
motor neurons of the brainstem and spinal cord, and UII and
UT immunoreactivity are present in neurons of the brainstem
involved in cardiovascular functions (Dun et al., 2001; Pelletier
et al., 2002; Jégou et al., 2006). UII, URP, and UT mRNAs
are also differentially expressed in peripheral tissues, including
notably the cardiovascular system (Ames et al., 1999; Vaudry
et al., 2010, 2015). These observations suggest that, in fish as
in mammals, UII/URPs may act centrally and peripherally to
control cardiovascular activity. Indeed, intracerebrovenricular
(ICV) injection of UII and to a lesser extent URPs in the rainbow
trout Onchorynchus mykiss (Le Mével et al., 1996; Vanegas et al.,
2015) and in the eel Anguilla japonica (Nobata et al., 2011),
and UII in mammals (Watson and May, 2004) elevates blood
pressure but also accelerates heart rate. Since, in these studies,
heart rate did not counter-regulate blood pressure elevation as
might be expected, it appears that the cardiac baroreflex was
impaired following ICV injection of UII/URPs. In mammals,
the cardiovascular effects of peripherally administered UII are
variable, depending upon the species used and the presence or
absence of anesthesia, inasmuch as increase or decrease in blood
pressure mostly associated with cardiac positive chronotropic
action are observed in rats, sheep and monkeys (Watson and
Abbreviations: BRS, baroreflex sensitivity; CNS, central nervous system; DVMN,
dorsal vagal motor nucleus; ECG, electrocardiographic; IA, intra-arterial; ICV,
intracerebroventricular; NTS, nucleus tractus solitarii; PDA, dorsal aortic blood
pressure; SBP, systolic blood pressure; UII, urotensin II; URP, urotensin II-related
peptide; URP1, urotensin II-related peptide 1; URP2, urotensin II-related peptide
2; UT, urotensin II receptor.
May, 2004). In trout and eel however, a consistent increase in
the dorsal aortic blood pressure is observed following intra-
arterial (IA) injection of UII and to a lesser extent URP1 but
not URP2 (Le Mével et al., 1996; Nobata et al., 2011; Vanegas
et al., 2015), but the baroreflexogenic bradycardia only occurs
after UII injection in trout. Since the cardiac baroreflex response
is an essential component of the cardiovascular regulation that
buffers abrupt changes in blood pressure tomaintain homeostasis
(La Rovere et al., 2008; Olson, 2011), we decided to clarify the
change in the cardiac baroreflex sensitivity (BRS) after ICV and
IA injections of trout UII in our established trout model (Lancien
et al., 2011).We contrasted the effects of UII with those of the two
paralogs URP1 and URP2.
MATERIALS AND METHODS
Peptides and Chemicals
Trout UII, zebrafishURP1, andURP2 (Waugh andConlon, 1993;
Tostivint et al., 2013) were synthesized as previously described
(Chatenet et al., 2004; Lancien et al., 2004). Table 1 summarizes
the physico-chemical characteristics of the synthetic peptides.
The peptides were dissolved in Ringer’s solution (vehicle) and
stored in stock solutions at −25◦C. Immediately before use,
UII, URP1, or URP2 were diluted to the desired concentration
with Ringer’s solution. The composition of the Ringer’s solution
was (in mM): NaCl 124, KCl 3, CaCl2 0.75, MgSO4 1.30,
KH2PO4 1.24, NaHCO3 12, glucose 10 (pH 7.8). All solutions
were sterilized by filtration through 0.22 µm filters (Millipore,
Molsheim, France) before injection.
Animals
Adults rainbow trout Oncorhynchus mykiss (251 ± 26 g body
wt, mean ± SEM, n = 98) of both sexes were purchased
TABLE 1 | Physico-chemical characteristics of the synthetized peptides.
Peptide Sequence RP-HPLC MS
tR (min)
a Purity (%) Calcd.b Obsd.c
Trout UII GGNSECFWKYCVTN 20.33 99.9 1389.55 1390.48
Zebrafish URP1 ACFWKYCVTN 19.40 96.6 1231.51 1232.69
Zebrafish URP2 VCFWKYCSQN 19.92 99.9 1274.52 1275.64
aRetention time determined by RP-HPLC on a Vydac 218TP54 C18 column (0.46 x 25 cm)
using a linear gradient (10–60% over 25min) of acetonitrile/TFA (99.9:0.1, v/v) at a flow
rate of 1 mL/min.
bTheorical monoisotopic molecular weight.
cm/z value assessed by MALDI-TOF-MS on a Voyager DE-PRO in the reflector mode with
α-cyano-4-hydroxycinnamic acid as a matrix.
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locally and transferred in a well-oxygenated and thermostatically
controlled water tank to the laboratory. All fish were kept
in a 1000-liter tank containing circulating dechlorinated and
aerated tap water (11–12◦C), under a standard photoperiod
(lights on 09:00 AM–08:00 PM). The fish were allowed at
least 3 weeks to acclimate under these conditions before
the experiments were started. Animal manipulations and
experimental protocols were approved by the Comité d’Ethique
Finistérien en Expérimentation Animale (authorization number
02142.01).
Experimental Procedures
The surgical procedures have previously been described in detail
(Lancien et al., 2004; Le Mével et al., 2012; Vanegas et al.,
2015). Briefly, anesthetized rainbow trout were equipped with
two electrocardiographic electrodes, a dorsal aortic cannula, an
ICV microguide, and a buccal catheter that was used to record
the buccal ventilatory pressure (not quantified in the present
study). After surgery, the animals were transferred to a 6-liter
blackened chamber supplied with dechlorinated and aerated
tap water (10–11◦C) that was both recirculating and through-
flowing. Oxygen pressure within the water tank (PwO2) and pH
were continuously recorded and maintained at constant levels
(PwO2 = 20 kPa; pH = 7.4–7.6). The trout were allowed to
recover from surgery and to become accustomed to their new
environment for 48–72 h.
Each day, after dorsal aortic blood pressure (PDA) and heart
rate were stabilized for at least 90 min, parameters were recorded
for 30 min and the different injection protocols begun. The
animals received no more than two ICV or IA injections of
peptide per day with a delay of at least 5 h between the injections.
Some trout received both ICV and IA injections, and in this case,
the delay between the two injections was 1 day, and the type of
injections was randomized among animals. No single fish was
studied for more than 2 days and control experiments revealed
that there was no significant change in performance over this
period.
Intracerebroventricular and Intra-Arterial
Administration of Peptides
For the ICV protocols, the injector was introduced within the
ICV guide prior to the beginning of a recording session which
lasted 30min. All injections were made at the 5min of the test
and the injector was left in place for a further 5min to allow
for complete diffusion of the agent and to minimize the spread
of substances upwards in the cannula tract. The fish received
first an ICV injection of vehicle (0.5 µl) and, 30min later, an
ICV injection of UII, URP1, or URP2 (5, 50 or 500 pmol in
0.5 µl). For IA injections, 5min after the beginning of the
recording session, 50 µl of vehicle, UII at doses of 5, 50 or 500
pmol, URP1 or URP2 at doses of 50 or 500 pmol was injected
through the dorsal aorta and immediately flushed by 150 µl of
vehicle.
Data Acquisition and Analysis of
Cardiovascular Variables
The ECG and PDA signals were recorded using standardized
electronic devices whose output were digitalized at 1000Hz,
FIGURE 1 | Raw tracings of 30-s duration in a single unanesthetized trout illustrating the changes observed in pulsatile dorsal aortic blood pressure
(PDA) and electrocardiographic (ECG) signals between the pre-injection period (A) and the post-injection period (B) after intracerebroventricular (ICV) injection
of 50 pmol UII. Note that, compared with the pre-injection period, ICV injection of UII produces an elevation of systolic blood pressure (SBP) but a decrease in the R–R
interval of the ECG (reflecting a tachycardia).
Frontiers in Neuroscience | www.frontiersin.org 3 February 2017 | Volume 11 | Article 51
Lancien et al. Urotensin II Peptides on Cardiac Baroreflex Sensitivity
visualized on the screen of a PC during the 30-min recording
period and finally stored using PowerLab 4/30 data acquisition
system (ADInstruments, Oxford, England) and LabChart
Pro software (v.7.0; ADInstruments, Oxford, England)
(Vanegas et al., 2015). ECG and PDA signals were then
processed off-line with custom-made programs written in
LabView 6.1 (Laboratory Virtual Instrument Engineering
Workbench, National Instruments, Austin, USA). Recordings
were excluded from the analysis if they contained excessive
artifacts on ECG and PDA signals. For all protocols, the entire
25-min post-injection segments of ECG and PDA signals
were selected after ICV or IA injections of vehicle, UII,
URP1, or URP2.
The R–R intervals (reflecting the time between each R wave of
the ECG), systolic blood pressure (SBP) and cardiac baroreflex
were calculated as previously described (Lancien et al., 2011).
The R–R intervals were determined after detection of the R
waves from the ECG recordings and SBP was identified from
the pulsatile PDA. Their mean values were calculated. R–R
interval and SBP time series were resampled at 2.56Hz to
obtain equidistant data points. The linear trend was removed
from the new time series and 29 segments of 256 data
points (100 s) overlapping by half were subjected to a Hanning
window. To investigate to what extend the input signal, SBP,
influences the output signal, the R–R interval, the coherence,
phase and transfer function spectra of SBP against the R–R
interval were determined (Lancien et al., 2011). A relatively
high coherence between the two signals and a negative phase
shift (SBP changes precedes R–R interval fluctuations) indicates
that the SBP mediates the changes in the R–R intervals. The
cardiac BRS was estimated as the mean of the gain of the
transfer function when the coherence was high and the phase
negative.
All calculations for R–R interval (in ms), SBP (in kPa), and
cardiac BRS (in kPa/ms) were made for the entire post-injection
period of 25min and the results were averaged for trout subjected
to the same protocol.
Statistical Analysis
Data are expressed as means + or ± SEM (standard error of
the mean) on histograms or in percentage change in the text.
For comparison between groups, the data were initially analyzed
using a one-way ANOVA followed by the Dunnett’s test for
comparisons between vehicle-injected trout and trout receiving
peptides. A value of P < 0.05 was considered significant. The
statistical tests were performed and the graphs constructed using
GraphPad Prism 5.0 (GraphPad, San Diego, CA).
RESULTS
Cardiac Baroreflex Sensitivity to Central
UII, URP1, and URP2
Figure 1 illustrates 30-s recordings of pulsatile PDA and ECG
signals taken during the pre-injection period (Figure 1A) and
during the post-injection period (Figure 1B) after ICV injection
of 50 pmol UII. Comparison of the post-injection and the pre-
injection signals revealed that UII caused a marked elevation in
SBP associated with a sharp reduction of the R–R interval of the
ECG.
The histograms in Figure 2 summarize the average changes
in R–R interval and SBP (Figure 2A) and in BRS (Figure 2B)
after ICV injection of vehicle or a range of doses (5–500 pmol)
of UII. Compared with vehicle-injected trout, UII produced a
gradual increase in SBP. The threshold dose for a statistically
significant effect on SBP was 50 pmol and, at this dose, the R–R
interval decreased significantly (Figure 2A). These effects on the
two cardiovascular variables remained significant up to the 500-
pmol dose (Figure 2A). Figure 2B demonstrates that the BRSwas
dose-dependently reduced following ICV injection of UII. The
threshold dose for a statistically significant effect on BRS was 50
pmol (−55%; 1450 ± 165 ms/kPa vs. 3240 ± 300 ms/kPa; P <
0.05) and the maximum decrease was observed for the 500-pmol
dose.
The effect of URP1 and URP2 on the cardiovascular variables
and cardiac BRS are summarized in Figures 3, 4, respectively. In
contrast to UII, ICV injection of URP1 provoked no significant
change in SBP and the R–R interval (Figure 3A). URP1 tended
to reduce BRS but this effect was not statistically significant
even at the highest dose (Figure 3B). Only the 500-pmol dose
of URP2 caused a significant increase in SBP without changing
significantly the R-R interval (Figure 4A) but, at this 500-pmol
FIGURE 2 | Histograms showing (A) the R–R intervals (scale on the left) and
the SBP values (scale on the right), (B) the BRS during the 5–30min period
after intracerebroventricular injection of 0 (vehicle, n = 24), 5 pmol (n = 8), 50
pmol (n = 7) and 500 pmol (n = 9) UII. n, number of trout. *P < 0.05 vs.
vehicle.
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FIGURE 3 | Histograms showing (A) the R–R intervals (scale on the left) and
the SBP values (scale on the right), (B) the BRS during the 5–30min period
after intracerebroventricular injection of 0 (vehicle, n = 20), 5 pmol (n = 9), 50
pmol (n = 11) and 500 pmol (n = 10) URP1. n, number of trout.
dose, URP2 evoked a significant depression in BRS (−47%,
1850± 290ms/kPa vs. 3470± 240 ms/kPa, P< 0.05; Figure 4B).
Cardiac Baroreflex Sensitivity to Peripheral
UII, URP1, and URP2
Figure 5 illustrates 30-s recordings of pulsatile PDA and ECG
signals taken during the pre-injection period (Figure 5A) and
during the post-injection period (Figure 5B) after IA injection
of 50 pmol UII. Comparison of the post-injection and the pre-
injection signals revealed that UII caused a marked elevation
in SBP associated with a potent increase in the R–R interval of
the ECG.
The effects of IA injection of vehicle or a range of doses of
UII (5–500 pmol) on the cardiovascular variables and BRS are
summarized in Figure 6. UII provoked a clear dose-dependent
increase in SBP with a threshold dose of 50 pmol for a
significant effect and a maximum hypertension at the 500-
pmol dose (Figure 6A). In marked contrast with the response
observed after ICV injection, the R–R interval increased up
to the 50-pmol dose and then returned to baseline level at
the 500-pmol dose (Figure 6A). Interestingly, and compared to
vehicle-injected trout, there was no change in the BRS using the
lowest picomolar doses of UII (50 pmol; 2530 ± 270 ms/kPa vs.
FIGURE 4 | Histograms showing (A) the R–R intervals (scale on the left) and
the SBP values (scale on the right), (B) the BRS during the 5–30min period
after intracerebroventricular injection of 0 (vehicle, n = 30), 5 pmol (n = 13), 50
pmol (n = 14) and 500 pmol (n = 9) URP2. n, number of trout. *P < 0.05 vs.
vehicle.
2600± 180 ms/kPa; P < 0.05) but the highest dose of UII caused
a 2-fold decrease in the BRS (Figure 6B).
The effect of URP1 and URP2 on the cardiovascular variables
and cardiac BRS are depicted in Figures 7, 8, respectively.
Only the highest dose of URP1 (500 pmol) elevated SBP but
decreased the R–R interval (Figure 7A). The attenuation of
the BRS was only significant after IA injection of this highest
dose of URP1 (−53%; 1540 ± 250 ms/kPa vs. 3330 ± 290
ms/kPa, P < 0.05; Figure 7B). The IA injection of URP2
was devoid of effect on the cardiovascular variables and BRS
(Figure 8).
DISCUSSION
Our study represents the first attempt in any animal species to
quantify the changes in spontaneous cardiac BRS after ICV and
IA injections of UII and URPs. The inhibitory effect of UII on
the BRS after ICV injection of low picomolar doses, and its
absence of effect after peripheral injection of equimolar doses
suggests that only the central urotensinergic system is involved
in the attenuation of the BRS. In addition, the limited and quite
divergent BRS effects of the two structurally UII-related peptides
URP1 and URP2, that share the cyclic hexapeptide core sequence
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FIGURE 5 | Raw tracings of 30-s duration in a single unanesthetized trout showing the changes observed in pulsatile dorsal aortic blood pressure
(PDA) and electrocardiographic (ECG) signals between the pre-injection period (A) and the post-injection period (B) after intra-arterial (IA) injection of 50 pmol
UII. Note that, compared with the pre-injection period, IA injection of UII provokes an increase in SBP and in the R–R interval of the ECG (reflecting a bradycardia).
of UII but differ in the N- and C-terminal regions (Table 1),
emphasize the importance of the amino-acid residues flanking
the N- and C-terminus of the cyclic region of the fish UII-
molecule for full interaction with the fish UT receptor. This
observation also indicates that the action of UII is specific for this
peptide.
The baroreflex has been conserved across vertebrate’s
evolution (Bagshaw, 1985; Van Vliet and West, 1994) and, in fish
as in mammals, the spontaneous BRS can be measured by means
of cross spectrum analysis of R–R interval and SBP variabilities
(Head et al., 2001; La Rovere et al., 2008; Lancien et al., 2011).
This technique offers the great advantage to prevent the use
of any stressful surgical interventions for loading or unloading
the baroreceptors and circumvents the use of vasoactive drugs
to evoke a baroreflex response, drugs that may interfere
with baroreflex functioning. However, using this approach, we
assessed only one aspect of the baroreflex loop, i.e., the baroreflex
regulation of heart rate, but not the baroreflex regulation of
vascular tone.
Central Effects of UII and URPs
In fish, the primary baroreceptor sites are the gills (Ristori and
Dessaux, 1970; Nilsson and Sundin, 1998; Armelin et al., 2016).
Afferent baroreceptive activity runs along the glossopharyngeal
(IXth cranial nerve) and along the vagus (Xth cranial nerve)
to reach the medulla oblongata. Little is known regarding the
central neuroregulatory mechanisms involved in the baroreflex
responses in fish, except that glutamatergic pathways within
the caudal part of the nucleus tractus solitarii (NTS) play a
key role to transmit baroreceptive information to the dorsal
vagal motor nucleus (DVMN) and hence, to control the cardiac
vagal outflow (Taylor et al., 1999; Sundin et al., 2003). In
trout, we previously demonstrated that spontaneous increases
or decreases in SBP provoke a bradycardia or a tachycardia,
respectively, that are exclusivelymediated by the parasympathetic
nervous system and thus that the spontaneous BRS can be
considered as an index of parasympathetic activity to the heart
(Lancien and Le Mével, 2007). The level at which UII/URPs
upon ICV injection mimic the possible action of the endogenous
urotensinergic system(s) on the neural networks involved in
the baroreflex response in trout, and notably on its cardio-
vagal inhibitory component, cannot be established from the
present experiments. However, some working hypotheses can
be proposed. Since the exogenous peptides were injected into
the third ventricle at the level of the nucleus preopticus, a
nucleus homologous to the paraventricular nucleus of mammals,
it is reasonable to speculate that UII/URPs might primarily
affect the activity of preoptic neuropeptidergic neurons like
arginine vasotocin and isotocin neurons that project toward
critical cardiovascular brainstem nuclei including the NTS and
the DVMN (Batten et al., 1990; Saito et al., 2004). In addition,
the urotensin peptides may diffuse within the cerebrospinal
fluid toward the fourth ventricle to control the activity of
these cardiovascular nuclei. Since we previously demonstrated
that, after peripheral injection of UII, bradycardia may arise
from adrenergic-mediated activation of the cardio-inhibitory
baroreflex (Le Mével et al., 1996), we can speculate that the
reduced BRS after ICV injection of UII may also be due to
blockage of central adrenergic pathways. Neuroanatomical and
molecular data from various teleost species provide some clues
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FIGURE 6 | Histograms showing (A) the R–R intervals (scale on the left) and
the SBP values (scale on the right), (B) the BRS during the 5–30min period
after intra-arterial injection of 0 (vehicle, n = 20), 5 pmol (n = 6), 50 pmol (n =
10) and 500 pmol (n = 7) UII. n, number of trout. *P < 0.05 vs. vehicle.
for these hypotheses. UT is expressed in the teleost brain (Lu
et al., 2006) and UII immunoreactivity and URP2 expression
are seen in the region surrounding the fourth ventricle (Yulis
and Lederis, 1988; Parmentier et al., 2011; Quan et al., 2015)
while URP1 is notably expressed in the NTS and the glosso-
pharyngeal motor nuclei (Nobata et al., 2011; Quan et al.,
2015). Whether UII/URP neurons present within the brainstem
contribute more precisely to the control of the BRS by interacting
with baroreflex afferent inputs at the level of the NTS remains to
be elucidated.
Our results demonstrating that third ventricle injection of
native UII in trout causes an attenuation of the BRS can be
compared with previous cardiovascular studies conducted with
UII in mammals. As previously mentioned, in normotensive
and hypertensive unanesthetized rats (Lin et al., 2003) and in
unanesthetized sheep (Watson et al., 2003), ICV administration
of UII causes pressor and tachycardic responses through
activation of the sympathetic system indicating that, in these
species, also the cardiac baroreflex response is impaired. Studies
conducted on unanesthetized sheep to test this hypothesis
demonstrated that, after ICV infusion of UII, the cardiac
baroreflex response is effectively blunted since no changes
occur in the cardiac sympathetic nerve activity in spite of
an increase in blood pressure (Hood et al., 2005). Since,
FIGURE 7 | Histograms showing (A) the R–R intervals (scale on the left) and
the SBP values (scale on the right), (B) the BRS during the 5–30min period
after intra-arterial injection of 0 (vehicle, n = 19), 50 pmol (n = 14) and 500
pmol (n = 11) URP1. n, number of trout. *P < 0.05 vs. vehicle.
in sheep, ICV UII also stimulates the sympatho-adrenal axis
resulting in elevation of plasma epinephrine (Watson et al.,
2003) and since propranolol blocks UII-induced tachycardia
(Hood et al., 2005), an increase in plasma level of epinephrine
together with preservation of cardiac sympathetic nerve activity
levels was postulated to be responsible for the chronotropic
effect of centrally administered UII (Hood et al., 2005).
Consequently, the cardiac baroreflex response to an increase
in blood pressure after ICV injection of UII, in mammals, is
probably impaired through the inability of central baroreflex
networks to drive sufficient vagal cardiac inhibitory influx and
to block cardiac sympathetic activity. It is known that, in
mammals, the central cardiomodulatory action of UII is site-
dependent as local administration of UII in discrete brain nuclei
produces differential heart rate responses (Lin et al., 2003).
Interestingly, a recent study in conscious rat demonstrates that
micro-injection of UII within the nucleus ambiguus, a key site
controlling parasympathetic cardiac tone, elicits a bradycardia,
indicating the involvement of UII in controlling vagal outflow
(Brailoiu et al., 2014). The regulation of the baroreflex in
fish is probably as complex as in mammals, and further
studies are required to determine more precisely the impact of
UII/URPs on the cardio-vagal component of the baroreflex, as
well as the potential effects of these peptides on sympathetic
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FIGURE 8 | Histograms showing (A) the R–R intervals (scale on the left) and
the SBP values (scale on the right), (B) the BRS during the 5–30min period
after intra-arterial injection of 0 (vehicle, n = 19), 50 pmol (n = 11), and 500
pmol (n = 9) URP2. n, number of trout. *P < 0.05 vs. vehicle.
outflow to cardiovascular and chromaffin tissues. We previously
demonstrated that, after ICV injection of native neuropeptides
in trout, angiotensin II (Lancien and Le Mével, 2007), pituitary
adenylate cyclase-activating polypeptide and vasoactive intestinal
peptide (Lancien et al., 2011) decrease BRS. The present study
adds UII and to a lesser extend URP2 as new candidates acting
centrally as neuromodulators or neurotransmitters to control the
cardiac baroreflex.
Peripheral Effects of UII and URPs
The bradycardic response to UII-induced hypertension is
parasympathetically-mediated since, in atropinized trout, this
bradycardia is abolished (Vanegas et al., 2016). In the present
study, ICV or IA administration of UII at its lowest doses
caused similar hypertension but in contrast to its ICV effects,
peripheral UII provoked a bradycardia and the BRS was not
disturbed. These data support the idea that, after peripheral
administration, UII does not affect vagal feedback gain on the
heart. Nonetheless, a significant decrease in BRS was observed
with the largest dose of UII. Since the BRS reduction to the
highest dose of IA administered UII was very similar to that
observed after ICV injection of the same dose, we assume that
this effect was mediated through a neurogenic pathway after
diffusion of UII to critical target sites in the brain. However,
because UT is also strongly expressed in the teleost heart
(Lu et al., 2006), we cannot exclude a possible direct positive
chronotropic effect of large doses of UII counter-acting the
baroreflex response. According to the route of administration
the highest dose of URP1 and URP2 had opposite effect on the
BRS, URP2 being more efficient than URP1 in the brain and
inversely at the periphery. It remains to be determined whether
these opposite effects of URP1 and URP2 can be ascribed to
differential interaction with UT or to binding to distinct UT
subtypes. Moreover, since the two URPs are exclusively expressed
in the CNS, the physiological significance of URP1 on BRS
remains also to be ascertained.
Possible Physiological Significance
In humans, a decrease in the BRS is associated with hypertension
and cardiovascular tissue damages (La Rovere et al., 2008). In fish,
the essential role of the baroreflex is to prevent damage to organs
primarily at risk, such as the delicate respiratory vasculature
of the gills (Bagshaw, 1985). Consequently, endogenous UII, a
peptide that provokes inhibition of BRS after central exogenous
injection, may contribute to exacerbate the increase in blood
pressure and may have deleterious effects. In the periphery, UII
also causes hypertension but the maintenance of the BRS may be
beneficial to prevent excessive elevation of blood pressure. This
hypertension might be useful to correct hypotensive situations
in order to maintain tissue perfusion pressure. Further studies
are required to elucidate the site(s) and mechanisms of action
of UII/URPs on the baroreflex pathways in trout and to
determine under which circumstances the central and peripheral
urotensinergic systems are recruited to regulate blood pressure.
In conclusion, our study has shown that UII and to a
lesser extent URPs interact with CNS blood pressure-regulating
structures, not only to elevate blood pressure and heart rate but
also to reduce BRS. Conversely, at the periphery, UII at low
picomolar doses increases blood pressure and decreases heart
rate but does not alter BRS.
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